Medicare Part D beneficiaries will pay more for biosimilar drugs (are similar — but not identical — to the brand-name drug) due to Obamacare. Why, drug makers are required by law to provide 50 percent discounts for brand-name biologics when Part D beneficiaries reach the coverage gap; the law does not apply to biosimilar drugs.
Why is this important? In a 2014 report from the RAND Corporation, these medicines are expected to cost 10 percent to 30 percent less than brand-name biologics and would lower the United States health care bill by estimated $44 billion in the next several years. Read article here…..
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.